Evidence map›Paper›PMID 33827417›Full record

ArticleJournal of neurodevelopmental disorders2021

Spoken language outcome measures for treatment studies in Down syndrome: feasibility, practice effects, test-retest reliability, and construct validity of variables generated from expressive language sampling.

Angela John Thurman, Jamie O Edgin, Stephanie L Sherman, Audra Sterling, Andrea McDuffie, Elizabeth Berry-Kravis, Debra Hamilton, Leonard Abbeduto

Abstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Expressive Language Sample Concordance With ADOS-2 Scores: Autism, Down Syndrome, Fragile X Syndrome.American journal on intellectual and developmental disabilities · 2026
    Article
  4. Article
  5. Article
  6. Language and Ageing in Adults With Down Syndrome: An Analysis of Receptive and Expressive Language Measures.Journal of applied research in intellectual disabilities : JARID · 2025
    Article
  7. A Review of Clinical Trials in Down Syndrome.International review of research in developmental disabilities · 2025
    Article
  8. Article
  9. Consistency and reliability of automated language measures across expressive language samples in autism.Autism research : official journal of the International Society for Autism Research · 2023
    Article
  10. Article
  11. Article
  12. Mental State Language Development in Children With Down Syndrome Versus Typical Development.American journal on intellectual and developmental disabilities · 2022
    Article
  13. Evaluating Verbal Fluency Outcome Measures in Children With Down Syndrome.American journal on intellectual and developmental disabilities · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Angela John ThurmanMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA. ajthurman@ucdavis.edu.ORCID 0000-0003-4220-7897
Jamie O EdginDepartment of Psychology, University of Arizona, Tucson, AZ, USA.
Stephanie L ShermanDepartment of Human Genetics, Emory University, Atlanta, GA, USA.
Audra SterlingWaisman Center and Department of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, WI, USA.
Andrea McDuffieMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA.
Elizabeth Berry-KravisDepartments of Pediatrics, Neurological Sciences and Biochemistry, Rush University Medical Center, Chicago, IL, USA.
Debra HamiltonDepartment of Human Genetics, Emory University, Atlanta, GA, USA.
Leonard AbbedutoMIND Institute, University of California Davis Health, 2825 50th Street, Sacramento, CA, USA.

Funding

UC Davis Clinical and Translational Science CenterUL1TR001860 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KENYON, NICHOLAS J., LYLES, COURTNEY REES · 2016 to 2025
$47.3M
UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JUDY A. VAN DE WATER · 2020 to 2026
$9.7M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HERTZ-PICCIOTTO, IRVA · 2013 to 2019
$8.5M
Expressive Language Sampling as an Outcome MeasureR01HD074346 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBEDUTO, LEONARD J. · 2013 to 2017
$3.9M
National Institute of Child Health and Human Development P50HD103526National Institute of Child Health and Human Development R01HD074346NCATS NIH HHS UL1 TR000002NCATS NIH HHS UL1 TR001860NICHD NIH HHS P50 HD103526NICHD NIH HHS R01 HD074346NICHD NIH HHS U54 HD079125
6 · The paper itself

Abstract

backgroundThe purpose of this study was to evaluate expressive language sampling (ELS) as a procedure for generating spoken language outcome measures for treatment research in Down syndrome (DS). We addressed (a) feasibility, (b) practice effects across two short-term administrations, (c) test-retest reliability across two short-term administrations, (d) convergent and discriminant construct validity, and (e) considered comparisons across the conversation and narration contexts.

methodParticipants were 107 individuals with DS between 6 and 23 years of age who presented with intellectual disability (IQ < 70). The utility of ELS procedures designed to collect samples of spoken language in conversation and narration were evaluated separately. Variables of talkativeness, vocabulary, syntax, utterance planning, and articulation quality, derived from transcripts segmented into C-units (i.e., an independent clause and its modifiers), were considered. A 4-week interval was used to assess practice effects and test-retest reliability. Standardized direct assessments and informant report measures were collected to evaluate construct validity of the ELS variables.

resultsLow rates of noncompliance were observed; youth who were under 12 years of age, had phrase-level speech or less, and had a 4-year-old developmental level or less were at particular risk for experiencing difficulty completing the ELS procedures. Minimal practice effects and strong test-retest reliability across the 4-week test-retest interval was observed. The vocabulary, syntax, and speech intelligibility variables demonstrated strong convergent and discriminant validity. Although significant correlations were found between the variables derived from both the conversation and narration contexts, some differences were noted.

conclusionThe ELS procedures considered were feasible and yielded variables with adequate psychometric properties for most individuals with DS between 6 and 23 years old. That said, studies of outcome measures appropriate for individuals with DS with more limited spoken language skills are needed. Context differences were observed in ELS variables suggest that comprehensive evaluation of expressive language is likely best obtained when utilizing both contexts.

Indexed as

Down SyndromeLanguageAdolescentAdultChildChild, PreschoolFeasibility StudiesHumansOutcome Assessment, Health CareReproducibility of ResultsYoung AdultClinical trialsDown syndromeExpressive languageExpressive language samplingOutcome measuresPsychometricsTreatment

Identifiers

PMID33827417
PMCPMC8028777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.